Photo credit: www.sciencedaily.com
Testicular cancer, while less common than breast or prostate cancer, is the leading solid tumor type diagnosed in males aged 15 to 35, with around 10,000 cases identified each year in the United States.
Aiming to enhance surgical practices, improve long-term prognoses, and reduce mortality rates among individuals with testicular cancer, a research project led by Clint Cary, M.D., MPH, MBA, from the Indiana University School of Medicine and the Regenstrief Institute has established that the traditional open surgery method for removing lymph nodes located behind the intestines is the preferred treatment for male patients whose cancer remains confined to the abdomen.
This open surgical technique entails making an incision in the abdominal area, allowing direct visualization and access to the surgical field. For suitable candidates, the success rates in treating cancer with this method are notably high, thanks to practitioners’ extensive experience and ongoing advancements in technique, particularly in specialized medical centers.
The research utilized data from the Indiana University Testicular Cancer database, encompassing 165 patients with clinical stage I or II testicular cancer who had not undergone prior chemotherapy. The IU School of Medicine’s Department of Urology is recognized as one of the leading treatment centers for testicular cancer in the U.S., consistently achieving better surgical outcomes and minimizing adverse effects, such as infertility. Key indicators of the study included minimal blood loss, short recovery periods, and infrequent serious postoperative complications.
According to Dr. Cary, the findings suggest that it is crucial for men and their families to discuss potential treatment options with their urologist before proceeding, especially considering factors like body mass index (BMI) and complication risks. The results can serve as a standard for patients and healthcare providers when evaluating treatment choices.
“As a urologist at Indiana University, I frequently perform lymph node dissections on men with limited metastatic cancer who have not been treated with chemotherapy,” stated Dr. Cary. “In my research role, I focus on understanding how clinical decisions impact patient outcomes and quality of life, whether we uphold established treatment practices or explore innovative surgical methods.”
“This research exemplifies how combining clinical practice with a research-focused environment enhances our understanding and the provision of meaningful care for patients and physicians alike. We consistently seek improvement in surgical results, and we are initiating a randomized trial to compare two surgical techniques for lymph node extraction to assess their differences in recovery post-surgery.”
It is worth noting that this research did not include a direct comparison between robotic surgery and open surgery techniques. Although robotic approaches may provide advantages for surgeons and patients alike, the authors highlight the limited comparative data available due to the small number of robotic procedures performed for testicular cancer.
The researchers ultimately concluded that for patients requiring lymph node removal due to testicular cancer—especially those facing higher risks of complications—open surgery remains the most effective and standard method of treatment.
The study titled “Contemporary short-term peri-operative outcomes of open primary retroperitoneal lymph node dissection” is published in BJU International, with support from the Department of Urology at IU School of Medicine. Dr. Cary served as the principal investigator.
The paper’s co-authors include Jacob D McFadden, Timothy A Masterson, and Clint Cary, all affiliated with the Indiana University School of Medicine’s Department of Urology.
Source
www.sciencedaily.com